Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer

Introduction. A number of drugs, which improve overall survival and quality of patients’ life, became available for treatment of metastatic castration-resistant prostate cancer (mCRPC). enzalutamide and abiraterone are the only two hormonal drugs increasing survival and approved for the treatment of mCRPC patients in Russia. The aim of the current study was to develop a pharmacoeconomic tool that calculates direct medical costs (price of the drugs) of using enzalutamide or abiraterone for treatment of chemotherapy-naïve patients with mCRPC from the Russian regional healthcare systems perspective. Materials and methods. The calculator is based on a published pharmacoeconomic model of using enzalutamide or abiraterone for the 1st line treatment of mCRPC. Current regional medication prices, which explain the biggest share of direct medical treatment costs, are automatically accounted for 84 Russian regions (except nenetsky AO). The calculator also provides estimates of number of chemotherapy-naïve patients, who are eligible for enzalutamide or abiraterone treatment in each region. Results. Costs of using enzalutamide or abiraterone are almost equal on the federal level, but the differences in the costs between these two medications are higher than 10% in 15 Russian regions. Conclusions. Possible differences in costs of using enzalutamide or abiraterone should be accounted during planning of state procurements on the regional level.

1. Mortality by causes of death in 2017. Rosstat (in Russian). [Electronic resource] URL: http://www.gks.ru/free_doc/new_site/population/demo/demo24-2.xls. Accessed: 05.10.2018.

2. Malignant neoplasms in Russia in 2017 (morbidity and mortality). Edited by A. D. Kaprina, V. V. Starinsky, G. V. Petrova. Moscow. 2018; 250 s. (in Russian).

3. Clinical recommendations: prostate cancer. Association of Oncologists of Russia (in Russian). [Electronic resource] URL: http://oncology-association.ru/files/clinical-guidelines_adults/rak_predstatelnoy_zhelezy.pdf. Accessed: 05.10.2018.

4. Instructions for the medical use of the drug KSOFIGO. State register of medicines (in Russian). [Electronic resource] URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=ca833164-d533-4dae-8b94-d6fdee7465d9&t=. Accessed: 05.10.2018.

5. Tannock I. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. new england Journal of Medicine. 2004; 351 (15): 1502-1512.

6. De Bono J. S. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. The Lancet. 2010; 376 (9747): 1147-1154.

7. Ryan C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. new england Journal of Medicine. 2013; 368 (2): 138-148.

8. Rathkopf D. E. et al. Updated interim efficacy analysis and longterm safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior 34 chemotherapy (COU-AA-302). european urology. 2014; 66 (5): 815- 825.

9. Ryan C. J. et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebocontrolled phase 3 study. The Lancet Oncology. 2015; 16 (2): 152-160.

10. De Bono J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. new england Journal of Medicine. 2011; 364 (21): 1995-2005.

11. Fizazi K. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. The lancet oncology. 2012; 13 (10): 983-992.

12. Scher H. I. et al. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. new england Journal of Medicine. 2012; 367 (13): 1187-1197.

13. Beer T. M. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. n engl J Med. 2014; 371 (5): 424-433.

14. Beer T. M. et al. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castrationresistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. european Urology. 2017; 71 (2): 151-154.

15. Kolbin A. S., Kurylev A. A., Pavlysh A. V. Comparison of clinicaleconomic evaluation of cabazitaxel and abiraterone for prostate cancer based on the results of clinical trials and real world data.kachestvennaya klinicheskaya praktika. 2015; (1): 18-31 (In Russian).

16. Avksentyev N. A., Derkach E. V. Pharmacoeconomic analysis of abiraterone for treatment of patients with metastatic castrate-resistant prostate cancer. Medicinskie texnologii. Ocenka i vybor. 2016; 25 (3): 54-67 (In Russian).

17. Avxentyev N. A., Frolov M. Y., Makarov A. S. Pharmacoeconomic analysis of enzalutamide and abiraterone for treatment of chemotherapy naive patients with metastatic castration resistant prostate cancer. Cancer Urology. 2017; 13 (3): 76-86. (In Russian). https://doi.org/10.17650/1726-9776-2017-13-3-76-86.

18. Mazina N. K., Mazin P. V. Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in postdocetaxel castration-resistant prostate cancer patients. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya / Farmakoekonomika. Modern pharmacoeconomics and pharmacoepidemiology. 2017; 10 (3): 12-21. (In Russian). https://doi.org/10.17749/2070-4909.2017.10.3.012-021.

19. Avksentyev N. A., Derkach E. V., Makarov A. S. Pharmacoeconomic evaluation of enzalutamide, abiraterone and cabazitaxel for the treatment of post-chemotherapy patients with metastatic castrationresistant prostate cancer. Medicinskie texnologii. Ocenka i vybor. 2018; 3 (33): 62-74.

20. Data on the limits of wholesale mark-ups and the limits of retail mark-ups on the prices of vital and essential drugs established in the constituent entities of the Russian Federation (data for the 3rd quarter of 2017) (in Russian). FAS Russia. [Electronic resource] URL: https://fas.gov.ru/documents/665519. Accessed: 06.10.2018.

21. Kirby M., Hirst C., Crawford E. D. Characterising the castrationresistant prostate cancer population: a systematic review. International Journal of Clinical Practice. 2011; 65 (11): 1180-1192.